The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.

Objective Systemic lupus erythematosus (SLE) is associated with increased susceptibility to infections, including herpes ...

Johnson & Johnson has won U.S. Food and Drug Administration fast-track designation for its investigational nipocalimab drug in adults with systemic lupus erythematosus, a chronic autoimmune disease.

Phase III results put obinutuzumab in line for approval ...

Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms; ...

A retrospective cohort study found that beta-blocker use is associated with a decreased risk for incident HF in certain SAID populations.

Systemic lupus erythematosus (SLE) is an autoimmune disease, in which the immune system that normally protects the body from invading microbes turns against the body's own cells. Researchers studied ...

The systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the seven major markets (7MM: the USA, France, ...

In a new study, right heart failure (RHF) hospitalizations of people with systemic lupus erythematosus (SLE) was associated with higher in-hospital mortality and non-fatal adverse outcomes. Lupus ...